Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis

NCT01256489 is registered in ClinicalTrials.gov with Massachusetts Eye and Ear Infirmary as lead sponsor.

NCT NCT01256489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01256489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis
Lead sponsor
Massachusetts Eye and Ear Infirmary
Phase
Phase 1/2
Overall status
Withdrawn
Start date
December 31, 2010
Completion date
January 31, 2015
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

corneal blindness, stevens-johnson syndrome